When do the patents on LEVOCETIRIZINE HYDROCHLORIDE expire, and when will LEVOCETIRIZINE HYDROCHLORIDE go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	LEVOCETIRIZINE HYDROCHLORIDE	levocetirizine dihydrochloride	SOLUTION;ORAL	210914-001	Apr 1, 2019	AA	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 13, 2026

vocetirizine Hydrochloride Investment Scenario & Patent/Exclusivity Fundamentals (US and Key Markets)
Levocetirizine hydrochloride is an established, off-patent second-generation antihistamine with limited remaining US value in originator-led patent exclusivity. Investment upside is mainly tied to (1) formulation and delivery IP, (2) regulated lifecycle events (reformulations, line extensions, pediatric/label expansion), and (3) branded supply economics (pricing power in select channels) rather than primary active-ingredient exclusivity.

What patents protect levocetirizine hydrochloride in the US?

Answer: Most active-ingredient protection for levocetirizine has long expired. The remaining US patent estate is typically concentrated in formulation, dosage form, manufacturing/process, and possibly method-of-use claims tied to specific patient populations or therapeutic regimens.

Which patent types still matter for investment

For levocetirizine, investors should map the residual patent estate to these categories:

Formulation patents: extended-release, orally disintegrating tablets, taste-masked granules, fixed-dose combinations.
Manufacturing/process patents: impurity control processes, crystallization polymorph control, scale-up methods, solvent or drying steps.
Salt/solid-state and particle engineering: polymorphs, hydrates, particle size distributions, and spray-dried or microencapsulated forms.
Device delivery: not common for this small molecule, but relevant for unit-dose or pediatric administration formats.
Method-of-use claims: narrower, harder to sustain against generic “label carve-outs,” but can delay certain competitors when claims align with label language.

How to build a litigable patent map (what to look for)

An actionable patent landscape for levocetirizine should include:

Orange Book-listed patents by NDA/ANDA (US exclusivity exposure by product).
Family-level status (earliest priority, continuation filings, terminal disclaimer dates).
Claim scope review focused on:
- composition claims (API + excipients + ratios)
- process claims (specific steps and parameters)
- solid-state claims (forms, characterization methods)
- method claims (label alignment)

When does levocetirizine lose exclusivity in the US (Orange Book timing)?

Answer: Generic availability is already broad in the US; any remaining exclusivity is likely product-specific for certain formulations and sponsor-specific exclusivity (if any) rather than API-level exclusivity.

Practical exclusivity framework for this drug

For levocetirizine hydrochloride, investors typically encounter:

No meaningful FDA exclusivity from brand owners for the base molecule (originator API expiration long past).
Orange Book patents still appearing for particular strengths/dosage forms where the sponsor secured formulation or process IP.
Market access driven by ANDA approvals and Para. IV history, not by sponsor exclusivity.

What matters for DCF modeling

Expected generic erosion window: model rapid share loss after the first low-cost ANDA.
Formulation premium persistence: only holds where a specific dosage form remains protected by formulation/process patents.
Channel-specific pricing: OTC or pharmacy channel pricing can remain higher than pure generics if competitors are limited by supply or claim design.

What generic entry risks exist for levocetirizine hydrochloride?

Answer: The core risk is straightforward genericization: once ANDAs exist and patents are not enforceable against specific formulations, entry pressure compresses margins.

Main generic launch scenarios

“Skinny” label generic with no formulation design changes
- Typically lowest regulatory and manufacturing cost.
- If originator patents are formulation-specific, generic can attempt non-infringement by reformulating.
Paragraph IV challenges against formulation/process Orange Book patents
- Higher probability when patents cover broad excipient ratios or generic-amenable process steps.
- Settlement risk is common in established, low-cost products, even when ultimate damages are limited.
Design-around with different dosage form
- For example: different release profile, different particle engineering approach, or different pediatric format.
- Can bypass formulation patents but may raise COGS.

How many ANDAs and which companies compete for levocetirizine hydrochloride?

Answer: The US market is populated by multiple generic suppliers for levocetirizine products. The investable question is not “existence of generic competition” but:

who supplies which strengths/dosage forms
who has stable contracts with wholesalers/PBM
who maintains lowest total landed cost at scale

Competitive fundamentals investors should track

Wholesale acquisition price (WAC) vs net price volatility by contract.
PBM formulary inclusion in allergy and respiratory seasons.
OTC-to-Rx channel migration for equivalent formulations where applicable.
Supply stability (plant capacity, batch failures, regulatory observations).

What is the FDA and Orange Book status of levocetirizine hydrochloride?

Answer: Levocetirizine hydrochloride has a mature regulatory footprint with broad generic access. Orange Book entries, when present, usually attach to particular NDAs/ANDAs and specific dosage forms rather than a single “API lockout.”

What “status” means for investors

Orange Book listings indicate patent linkages to specific product codes.
FDA approval type indicates whether a competitor is already on market.
Exclusivity and patents are relevant mainly to:
- delayed entry for linked products
- potential damages/royalty arrangements in settlements

What formulations are protected by patents for levocetirizine hydrochloride?

Answer: Protection is most likely around dosage form engineering rather than the molecule itself. The investable scope is formulation-specific.

Formulation areas that can sustain higher margins

Extended-release variants (if any protectable versions exist)
Orally disintegrating tablets with taste masking and fast disintegration
Pediatric liquid formulations with stability and impurity control
Fixed-dose combinations (API stacking with other allergy drugs) if protected by combination IP

How to diligence claim coverages vs real-world infringement

Compare the originator’s claim language on:
- excipient types and ranges
- coating materials and thickness
- release kinetics parameters
- manufacturing steps and acceptable impurity targets
For process patents, evaluate whether generic manufacturers use the same critical process parameters.

What patent litigation affects levocetirizine hydrochloride?

Answer: In established small molecules, litigation is usually centered on formulation/process Orange Book patents with limited damages exposure. The key for investment is whether any current disputes are:

actively blocking a major competitor
likely to end with a settlement that preserves higher pricing for a period
linked to a specific dosage form with material sales

What to monitor in the litigation pipeline

New ANDA submissions with Para. IV filings against listed patents
District court rulings that narrow or invalidate formulation claims
Federal Circuit outcomes affecting claim interpretation
Injunction outcomes that alter launch timelines

How does levocetirizine hydrochloride compare with cetirizine for market and IP value?

Answer: Cetirizine is a direct comparator and typically has broader product ecosystems, while levocetirizine competes on perceived tolerability and dosing convenience claims. From an investment standpoint, both face generic price pressure; the differentiator is whether a sponsor still holds enforceable formulation IP for specific product codes.

Investor decision lens

If levocetirizine has identifiable, enforceable formulation patents, it can sustain a premium on select NDCs.
If not, performance tracks generic antihistamine economics, with margins driven by:
- supply chain efficiency
- contracting leverage
- OTC brand support (if any specific branded line exists in-market)

What biosimilar or biologic risk applies to levocetirizine hydrochloride?

Answer: None. Levocetirizine hydrochloride is a small molecule antihistamine. The relevant competitor risk is generic ANDAs, not biosimilars.

What licensing deals and settlements shape levocetirizine economics?

Answer: For small-molecule generics, settlements usually take the form of:

delayed launch agreements tied to patent expiry or non-infringement positions
royalty-bearing arrangements for continued branded supply under a settlement framework
“design-around” pathways where the ANDA changes formulation to avoid infringement

What to model in a settlement-driven scenario

Launch delay length and which NDCs are protected
Territory scope (US only vs global)
Any supply obligations or exclusivity-like purchasing commitments
“Trigger dates” tied to court outcomes or patent invalidation

Which geographies still offer exclusivity or higher margin for levocetirizine hydrochloride?

Answer: Most high-income markets have mature generic access. Value concentrates where:

patent enforcement exists for formulation patents
regulatory exclusivity (rare for mature molecules) attaches to specific line extensions
local reimbursement supports branded or premium generics

Geographic diligence checklist

EU: verify if any formulation/process patents are still in force for marketed dosage forms.
UK: post-Brexit alignment for patent enforcement timing.
Canada/Australia: check which product codes still carry patent protection in local registers.
Emerging markets: identify if supply constraints reduce competitive price erosion.

What is the investment thesis for levocetirizine hydrochloride today?

Answer: The thesis is not “API exclusivity.” The thesis is:

Portfolio holding: secure specific protected formulations where infringement risk is manageable and market differentiation exists.
Execution economics: win on cost, stability, and manufacturing yield, since price compression is the base case.
Regulatory/label leverage: pursue line extensions and pediatric-use compliance where they create formulary traction.
Litigation optionality: monitor Para. IV and claim challenges only where they map to meaningful sales concentration.

Revenue exposure model (how businesses should think)

Base case assumptions:

rapid generic erosion for non-protected NDCs
margin dominated by contracting and volume commitments
incremental sales from protected dosage forms, if any, offset erosion

Upside triggers:

a defensible formulation patent estate surviving challenge
a settlement that preserves market share on key NDCs
successful switching to a proprietary pediatric or OTC-friendly format

Downside triggers:

entry of low-cost competitors across all strengths
court rulings narrowing remaining formulation claims
supply disruptions in specific factories causing lost share without price recovery

Key Takeaways

Levocetirizine hydrochloride is a mature, generically penetrated small molecule; active-ingredient exclusivity is not the primary investment driver.
Investable value, where present, is tied to product-code-specific formulation and process IP and to regulatory line extensions.
Competitive risk is dominated by ANDA-led generic entry; biosimilar risk is irrelevant.
The practical path to upside is winning on protected dosage forms and cost-of-goods, not expecting durable API monopoly economics.

FAQs

What NDC-level factors most affect levocetirizine pricing after generic entry?
Do formulation patents for levocetirizine typically cover excipient ratios, particle size, or release profile?
What Para. IV patterns are most common for established antihistamines like levocetirizine?
How should investors diligence pediatric liquid or ODT versions of levocetirizine for patent barriers?
What contracting levers (wholesaler vs PBM vs OTC) determine margin resilience for levocetirizine generics?

References (APA)

FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Drugs@FDA: Orange Book. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
FDA. (n.d.). Abbreviated New Drug Application (ANDA). U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-applications-anda

LEVOCETIRIZINE HYDROCHLORIDE Drug Patent Profile

When do Levocetirizine Hydrochloride patents expire, and when can generic versions of Levocetirizine Hydrochloride launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levocetirizine Hydrochloride

AI Deep Research

Questions you can ask:

Summary for LEVOCETIRIZINE HYDROCHLORIDE

US Patents and Regulatory Information for LEVOCETIRIZINE HYDROCHLORIDE